

# CITATION REPORT

List of articles citing

Risk factors for intrahepatic and extrahepatic  
cholangiocarcinoma in the United States: A  
population-based study in SEER-Medicare

DOI: 10.1371/journal.pone.0186643  
PLoS ONE, 2017, 12, e0186643.

**Source:** <https://exaly.com/paper-pdf/87049708/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
110	Primary Liver Tumors Other than Hepatocellular Carcinoma: Clinical and Molecular Pearls. <b>2018</b> , 17, 412-424		
109	Incretins and cancer of the bile duct in type 2 diabetes. <b>2018</b> , 363, k5155		0
108	Comprehensive Review of Molecular Mechanisms during Cholestatic Liver Injury and Cholangiocarcinoma. <b>2018</b> , 7,		5
107	Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-analysis. <b>2018</b> , 113, 1494-1505		38
106	The expression and clinicopathological role of CDX2 in intrahepatic cholangiocarcinoma. <b>2018</b> , 7, 106-111		4
105	Epigenome Remodeling in Cholangiocarcinoma. <b>2019</b> , 5, 335-350		18
104	Liver cancer: A leading cause of cancer death in the United States and the role of the 1945-1965 birth cohort by ethnicity. <b>2019</b> , 1, 162-169		30
103	Relapse patterns and predictors of IgG4-related diseases involved with autoimmune pancreatitis: A single-center retrospective study of 115 patients. <b>2019</b> , 20, 152-158		4
102	Crossing borders: A systematic review with quantitative analysis of genetic mutations of carcinomas of the biliary tract. <b>2019</b> , 140, 8-16		13
101	Therapeutic Potential of Pharmacoepigenetics in Cholangiocarcinoma. <b>2019</b> , 551-562		
100	Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies. <b>2019</b> , 111, 1263-1278		16
99	Multimodality Management of Localized Biliary Cancer. <b>2019</b> , 20, 58		4
98	Postbiliary drainage rates of cholangitis are impacted by procedural technique for patients with supra-ampullary cholangiocarcinoma: A SEER-Medicare analysis. <b>2019</b> , 120, 249-255		2
97	Molecular Pathogenesis of Cholangiocarcinoma. <b>2019</b> , 19, 185		103
96	Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. <b>2019</b> , 71, 104-114		144
95	Impact of body mass index on tumor recurrence among patients undergoing curative-intent resection of intrahepatic cholangiocarcinoma- a multi-institutional international analysis. <b>2019</b> , 45, 1084-1091		3
94	Cholangiocarcinoma: Epidemiology and risk factors. <b>2019</b> , 39 Suppl 1, 19-31		181

93	Is exposure to tobacco associated with extrahepatic cholangiocarcinoma epidemics? A retrospective proportional mortality study in China. <b>2019</b> , 19, 348	1
92	Cholangiocarcinoma. <b>2019</b> , 425-444	
91	Contemporary Tailored Oncology Treatment of Biliary Tract Cancers. <b>2019</b> , 2019, 7698786	4
90	Epidemiology of intrahepatic, perihilar, and distal cholangiocarcinoma in the French population. <b>2019</b> , 31, 678-684	8
89	Inflammation and Progression of Cholangiocarcinoma: Role of Angiogenic and Lymphangiogenic Mechanisms. <b>2019</b> , 6, 293	19
88	Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults. <b>2019</b> , 144, 707-717	10
87	Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013. <b>2019</b> , 125, 1489-1498	48
86	Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. <b>2020</b> , 72, 95-103	102
85	Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part I: Classification, diagnosis and staging. <b>2020</b> , 52, 1282-1293	21
84	Diagnostic accuracy of administrative database for bile duct cancer by ICD-10 code in a tertiary institute in Korea. <b>2020</b> , 19, 575-580	2
83	Alcohol Use and Gastrointestinal Cancer Risk. <b>2020</b> , 36, 175-181	9
82	Friend or Foe? An Unrecognized Role of Uric Acid in Cancer Development and the Potential Anticancer Effects of Uric Acid-lowering Drugs. <b>2020</b> , 11, 5236-5244	5
81	Association between nonalcoholic fatty liver disease and extrahepatic cancers: a systematic review and meta-analysis. <b>2020</b> , 19, 118	19
80	Epidemiology of Cholangiocarcinoma; United States Incidence and Mortality Trends. <b>2020</b> , 44, 885-893	18
79	Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials. <b>2020</b> , 151, 102975	8
78	Risk factors and characteristics of young patients with the biliary tract carcinoma: results of a project study for biliary surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. <b>2020</b> , 27, 571-580	2
77	New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma. <b>2020</b> , 9,	24
76	Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. <b>2020</b> , 126, 2666-2678	57

75	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <b>2020</b> , 17, 557-588	355
74	Effect of Statins on the Risk of Extrahepatic Cholangiocarcinoma. <b>2020</b> , 72, 1298-1309	8
73	Have incidence rates of liver cancer peaked in the United States?. <b>2020</b> , 126, 3151-3155	7
72	Surgical Treatments of Hepatobiliary Cancers. <b>2021</b> , 73 Suppl 1, 128-136	30
71	Pathogenesis of Cholangiocarcinoma. <b>2021</b> , 16, 433-463	16
70	Nonalcoholic fatty liver disease is associated with intrahepatic cholangiocarcinoma and not with extrahepatic form: definitive evidence from meta-analysis and trial sequential analysis. <b>2021</b> , 33, 62-68	5
69	Clinical Epidemiology of Cholangiocarcinoma. <b>2021</b> , 137-162	
68	Development and validation of a machine learning-based nomogram for prediction of intrahepatic cholangiocarcinoma in patients with intrahepatic lithiasis.. <b>2021</b> , 10, 749-765	1
67	Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic. <b>2021</b> , 30, 377-388	2
66	NAFLD exacerbates cholangitis and promotes cholangiocellular carcinoma in mice. <b>2021</b> , 112, 1471-1480	2
65	Underexpression of miR-126-3p in Patients with Cholangiocarcinoma. <b>2021</b> , 22, 573-579	2
64	New Breakthroughs for Liver Transplantation of Cholangiocarcinoma. <b>2021</b> , 8, 21-27	0
63	Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. <b>2021</b> , 71, 209-249	11229
62	Does Nonalcoholic Fatty Liver Disease Increase the Risk for Extrahepatic Malignancies?. <b>2021</b> , 17, 215-219	
61	Risk Stratification of Cholangiocarcinoma Patients Presenting with Jaundice: A Retrospective Analysis from a Tertiary Referral Center. <b>2021</b> , 13,	0
60	Liquid biopsy in cholangiocarcinoma: Current status and future perspectives. <b>2021</b> , 13, 332-350	12
59	Obesity and cholangiocarcinoma: A review of epidemiological and molecular associations. <b>2021</b> ,	0
58	Association between non-alcoholic fatty liver disease and the risk of biliary tract cancers: A South Korean nationwide cohort study. <b>2021</b> , 150, 73-82	2

57	The rate of cholangiocarcinoma in Caroli Disease A German multicenter study. <b>2021</b> ,	0
56	Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma. <b>2021</b> , 13,	6
55	Incidence and Mortality of Cancers of the Biliary Tract, Gallbladder, and Liver by Sex, Age, Race/Ethnicity, and Stage at Diagnosis: United States, 2013 to 2017. <b>2021</b> , 30, 1607-1614	0
54	Update on the association of hepatitis B with intrahepatic cholangiocarcinoma: Is there new evidence?. <b>2021</b> , 27, 4252-4275	0
53	The Role of microRNAs in Cholangiocarcinoma. <b>2021</b> , 22,	3
52	Metabolic disorders and the risk of cholangiocarcinoma. <b>2021</b> , 15, 999-1007	1
51	Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland. <b>2021</b> ,	1
50	Cholangiocarcinoma. <b>2021</b> , 7, 65	30
49	Vimentin-Positive Circulating Tumor Cells as Diagnostic and Prognostic Biomarkers in Patients with Biliary Tract Cancer. <b>2021</b> , 10,	
48	Targeted genomic profiling revealed a unique clinical phenotype in intrahepatic cholangiocarcinoma with fibroblast growth factor receptor rearrangement. <b>2021</b> , 14, 101168	2
47	Analysis of Risk Factors of Gallbladder Stones in the Elderly. <b>2021</b> , 11, 3912-3916	
46	Common features between neoplastic and preneoplastic lesions of the biliary tract and the pancreas. <b>2019</b> , 25, 4343-4359	11
45	Role of autophagy in cholangiocarcinoma: An autophagy-based treatment strategy. <b>2021</b> , 13, 1229-1243	2
44	Transcriptomic-Based Identification of the Immuno-Oncogenic Signature of Cholangiocarcinoma for HLC-018 Multi-Target Therapy Exploration. <b>2021</b> , 10,	6
43	Cholangiocarcinoma: new perspectives for new horizons. <b>2021</b> , 1-17	0
42	CHAPTER 7. Alcohol Intake and Cancer Risk. <b>2019</b> , 108-127	
41	Epidemiology and Risk Factors. <b>2019</b> , 1-10	1
40	Effect of liver fibrosis on survival in patients with intrahepatic cholangiocarcinoma: a SEER population-based study. <b>2020</b> , 11, 4438-4447	2

39	Menopausal hormone therapy and risk of biliary tract cancers. <b>2021</b> ,	0
38	Controversial risk factors for cholangiocarcinoma. <b>2021</b> , 34,	1
37	PCBP1 regulates the transcription and alternative splicing of metastasis-related genes and pathways in hepatocellular carcinoma. <b>2021</b> , 11, 23356	1
36	Results of Intrahepatic Cholangiocarcinoma Resections: a Single-Center Analysis.. <b>2022</b> , 1	
35	Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry.. <b>2021</b> ,	10
34	Inflammatory pathways and cholangiocarcinoma risk mechanisms and prevention. <b>2022</b> ,	
33	Neurological complications of GI cancers. <b>2022</b> , 365-386	
32	Comparison of Risk Factors for Cholangiocarcinoma and Hepatocellular Carcinoma: A Prospective Cohort Study in Korean Adults.. <b>2022</b> , 14,	0
31	Recurrence and prognosis in intrahepatic cholangiocarcinoma patients with different etiology after radical resection: a multi-institutional study.. <b>2022</b> , 22, 329	0
30	Understanding the genetic basis for cholangiocarcinoma. <b>2022</b> ,	
29	Postoperative survival of extrahepatic and intrahepatic cholangiocarcinoma after surgery: a population-based cohort.. <b>2022</b> , 12, e049789	
28	Incidence, Mortality Features and Lifetime Risk Estimation of Digestive Tract Cancers in an Urban District of Shanghai, China.	0
27	Role of molecular genetics in the clinical management of cholangiocarcinoma. <b>2022</b> , 7, 100505	2
26	Non-Alcoholic Fatty Liver Disease and Extrahepatic Cancers: A Wolf in Sheep's Clothing?. <b>2022</b> , 29, 4478-4510	0
25	A Novel Insight into Controversial Risk Factors of Intrahepatic Cholangiocarcinoma: A Mendelian Randomization Study.	
24	Clinical treatment of cholangiocarcinoma: an updated comprehensive review. <b>2022</b> , 100737	3
23	Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection.	
22	Secular trends of intrahepatic cholangiocarcinoma in a high endemic area: A population-based study. <b>2022</b> , 28, 3695-3705	

21	Examination on the risk factors of cholangiocarcinoma: A Mendelian randomization study. 13,	0
20	Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017.	2
19	Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant. <b>2022</b> , 13, 688-701	1
18	Current epidemiology of cholangiocarcinoma in western countries. <b>2022</b> ,	0
17	AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma.	4
16	Development and validation of a prognostic nomogram for extrahepatic bile duct adenocarcinoma. 12,	0
15	Circulating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma. 12,	0
14	The multidisciplinary management of cholangiocarcinoma.	1
13	Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma. <b>2022</b> , 12,	0
12	Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion. <b>2022</b> , 22, 1265-1274	0
11	Intrahepatic cholangiocarcinoma: The role of liver transplantation, adjunctive treatments, and prognostic biomarkers. 12,	0
10	Disparities in the Diagnosis and Treatment of Bile Duct Cancer in People with Disabilities: A National Cohort Study in South Korea. <b>2022</b> , 19, 16625	0
9	Metabolic Risk Factors for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease: A Prospective Study. <b>2022</b> , 14, 6234	0
8	Any Role for Microbiota in Cholangiocarcinoma? A Comprehensive Review. <b>2023</b> , 12, 370	0
7	Risk Assessment and Cholangiocarcinoma: Diagnostic Management and Artificial Intelligence. <b>2023</b> , 12, 213	0
6	Research Progress on Risk Factors of Cholangiocarcinoma. <b>2023</b> , 13, 4025-4031	0
5	Revision of potential prognostic markers of cholangiocarcinoma for clinical practice.	0
4	Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease. <b>2023</b> , 27, 251-273	0

- 3 Anthropometric indicators of adiposity and risk of primary liver cancer: A systematic review and dose-response meta-analysis. **2023**, 185, 150-163 ○
- 2 Microsomal Prostaglandin E Synthase-1 and -2: Emerging Targets in Non-Alcoholic Fatty Liver Disease. **2023**, 24, 3049 ○
- 1 Prolonged survival with first-line chemotherapy in advanced extrahepatic cholangiocarcinoma. **2023**, 16, e249681 ○